PSEUDOEXFOLIATION: LOOK WHAT ELSE WE FOUND:- A TERTIARY CARE EXPERIENCE FROM KASHMIR
Main Article Content
Keywords
Pseudoexfoliation syndrome, Pseudoexfoliation glaucoma, Peripheral artery disease, systemic vascular disease, Sensorineural Hearing Loss
Abstract
Purpose: To evaluate the systemic associations of pseudoexfoliation syndrome (PXS) and pseudoexfoliation glaucoma (PXG), emphasizing vascular and neurological manifestations, and to assess the prevalence of peripheral arterial disease (PAD) using objective diagnostic methods.Methods: This prospective, hospital-based cross-sectional study included 200 participants: 50 with PXS, 50 with PXG, and 100 age- and sex-matched controls. All subjects underwent comprehensive ophthalmic evaluation, including optical coherence tomography (OCT) and visual field analysis. Systemic assessment included history, clinical examination, serum homocysteine and lipid profile testing, pure tone audiometry for sensorineural hearing loss (SNHL), ankle-brachial index (ABI), and Doppler ultrasound of the anterior tibial and dorsalis pedis arteries to detect PAD.Results: Systemic comorbidities were significantly more prevalent in PXS and PXG groups than controls, including ischemic heart disease (p < 0.01), aortic aneurysm (p < 0.001), cerebrovascular disease (p < 0.01), PAD (p < 0.001), and SNHL (p < 0.001). PAD, confirmed by abnormal ABI and Doppler changes, emerged as a notable new association. There was no statistically significant difference in systemic involvement between PXS and PXG groups.Conclusion:Pseudoexfoliation is a systemic fibroelastotic disorder with significant vascular and neurological implications. PAD represents a newly identified and highly significant association, reinforcing the systemic nature of pseudoexfoliation. Early detection may guide broader systemic risk assessment and multidisciplinary management.
References
2. Schlotzer-Schrehardt UM, Koca MR, Naumann GO, Volkholz H. Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder? Arch Ophthalmol 1992; 110(12): 1752–6.
3. Streeten BW, Li ZY, Wallace RN, Eagle RC Jr, Keshgegian AA. Pseudoexfoliativefibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch Ophthalmol 1992; 110(12): 1757–2.
4. Schlotzer-Schrehardt U, Kuchle M, Hofmann-Rummelt C, Kaiser A, Kirchner T. Latent TGF-beta 1 binding protein (LTBP-1); a new marker for intra-and extraocular PEX deposits. Klin MonblAugenheilkd 2000; 216(6): 412–9.
5. Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol 1997; 124(5): 685–7.
6. Schumacher S, Schlotzer-Schrehardt U, Martus P, Lang W, Naumann GO. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet 2001; 357(9253): 359–60.
7. Ritland JS, Egge K, Lydersen S, Juul R, Semb SO. Exfoliative glaucoma and primary open-angle glaucoma: associations with death causes and comorbidity. Acta Ophthalmol Scand 2004; 82(4): 401–404.
8. Allingham RR, Loftsdottir M, Gottfredsdottir MS, Thorgeirsson E, Jonasson F, Sverisson T et al. Pseudoexfoliation syndrome in Icelandic families. Br J Ophthalmol 2001; 85(6): 702–707.
9. Plateroti P, Plateroti AM, Abdolrahimzadeh S, Scuderi G. Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma: A Review of the Literature with Updates on Surgical Management. J Ophthalmol. 2015; 2015: 370371.
10. Grzybowski A, Kanclerz P, Ritch R. The History of Exfoliation Syndrome. Asia Pac J Ophthalmol (Phila). 2019 Jan-Feb; 8(1): 55-61.
11. Mastronikolis S, Pagkalou M, Plotas P, Kagkelaris K, Georgakopoulos CD. Emerging roles of oxidative stressin the pathogenesis of pseudoexfoliation syndrome (Review). Exp Ther Med. 2022 Sep; 24(3): 602.
12. Jeng SM, Karger RA, Hodge DO, Burke JP, Johnson DH, Good MS. The risk of glaucoma in pseudoexfoliation syndrome. J Glaucoma. 2007 Jan;16(1):117-21.
13. Thorleifsson G, Magnusson KP, Sulem P, Walters GB, Gudbjartsson DF, Stefansson H et al. Common sequence variants in the LOXL1gene confer susceptibility to exfoliation glaucoma. Science 2007; 317(5843): 1397–1400.
14. Ovodenko B, Rostagno A, Neubert TA, Shetty V, Thomas S, Yang A et al. Proteomic analysis of exfoliation deposits. Invest Ophthalmol Vis Sci 2007; 48(4): 1447-57.
15. Zenkel M, Kruse FE, Junemann AG, Naumann GO, Schlotzer-Schrehardt U. Clusterin deficiency in eyes with pseudoexfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material. Invest Ophthalmol Vis Sci 2006; 47(5):1982–90.
16. Vessani RM, Ritch R, Liebmann JM, Jofe M. Plasma homocysteine is elevated in patients with exfoliation syndrome. Am J Ophthalmol 2003; 136(1): 41–46.
17. Aasved H. Study of relatives of persons with fibrillopathiaepitheliocapsularis (pseudoexfoliation of the lens capsule). Acta Ophthalmol (Copenh) 1975; 53(6): 879–86.
18. Ritch R. Exfoliation syndrome: clinical findings and occurrence in patients with occludable angles. Trans Am Ophthalmol Soc 1994; 92: 845–44.
19. Sood GC, Sofat BK, Mehrotra SK, Chandel RD. Capsular exfoliation syndrome. Br J Ophthalmol 1973;57(2):120–24.
20. Damji KF, Bains HS, Amjadi K, Dohadwala AA, Valberg JD, Chevrier Ret al. Familial occurrence of pseudoexfoliation in Canada. Can J Ophthalmol 1999; 34(5): 257–65.
21. Klouman OF. Psuedoexfoliation in ophthalmic practice. Acta Ophthalmol (Copenh) 1967; 45(6): 822–28.
22. Sharma S, Chataway T, Klebe S, Griggs K, Martin S, Chegeni N et al. Novel protein constituents of pathological ocular pseudoexfoliation syndrome depositsidentified with mass spectrometry. Mol Vis. 2018;24:801-17.
23. Ritch R, Schlotzer-Schrehardt U. Exfoliation (pseudoexfoliation) syndrome: toward a new understanding. Proceedings of the First International Think Tank. Acta Ophthalmol Scand 2001; 79(2): 213–17.
24. Oleggini R, Gastaldo N, Di Donato A. Regulation of elastin promoter by lysyl oxidase and growth factors: cross control of lysyl oxidase on TGF-beta1 effects. Matrix Biol 2007; 26(6):494–505.
25. Arnarsson AM. Epidemiology of exfoliation syndrome in the Reykjavik Eye Study. Acta Ophthalmol 2009; 87(Thesis 3):1–17.
26. Schlotzer-Schrehardt U, Zenkel M, Decking U, Haubs D, Kruse FE, Junemann A et al. Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci 2005, 46(6):2023–34.
27. Sarenac-Vulovic TS, Petrovic MAJ, Vulovic DJ, Pavlovic SM, Simovic S and Zdravkovic NS. Systemic manifestations of pseudoexfoliation. Ser J Exp Clin Res 2014; 15 (1): 29-32.
28. Elhawy E, Kamthan G, Dong CQ, Danias J. Pseudoexfoliation syndrome, a systemic disorder with ocular manifestations. Hum Genomics. 2012 Oct 10; 6(1): 22. doi: 10.1186/1479-7364-6-22.
29. Schlotzer-Schrehardt UM, Koca MR, Naumann GO, Volkholz H. Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder? Arch Ophthalmol 1992; 110: 1752–6.
30. Bleich S, Roedl J, Von Ahsen N, Schlotzer-Schrehardt U, Reulbach U, Beck G et al. Elevated homocysteine levels in aqueous humor of patients with pseudoexfoliation glaucoma. Am J Ophthalmol 2004; 138:162-4.
31. Yuksel N, Karabas VL, Arslan A, Demirci A, Caglar Y. Ocular hemodynamics in pseudoexfoliationsyndromeandpseudoexfoliation glaucoma. Ophthalmology. 2001 Jun; 108(6): 1043-9.
32. Hammer T, Schlotzer-Schrehardt U, Jünemann A. [Unilateral or asymmetric PEX syndrome? An electronmicroscopy study]. Klin Monbl Augenheilkd. 2000 Aug; 217(2): 100-8.
33. Patil A, Swiston C, Wallace RT, Paulson C, Conley ME, McCoy L et al. Exfoliation Syndrome and Exfoliation Glaucoma in the Navajo Nation. Vision (Basel). 2022 Oct 3; 6(4):61. doi: 10.3390/vision6040061.
34. Yilmaz A, Tamer L, Ates NA, Yildirim O, Yildirim H, Atik U. Is GST gene polymorphism a risk factor indeveloping exfoliation syndrome? Curr Eye Res. 2005 Jul; 30(7): 575-81.
35. Ritch R. Ocular and systemic manifestations of exfoliation syndrome. J Glaucoma. 2014 Oct-Nov; 23(8 Suppl 1):S1-8.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Younis Ahmad Dar
Senior Resident, Department of Ophthalmology, SKIMS Medical College, Bemina Srinagar, Jammu and Kashmir, India
Dr. Sheikh Sajjad
Professor and Head, Department of Ophthalmology, SKIMS Medical College, Bemina Srinagar, Jammu and Kashmir, India
Dr. Sadiya Aijaz
Senior Resident, Department of Ophthalmology, SKIMS Medical College, Bemina Srinagar, Jammu and Kashmir, India
Dr. Fajjr Shifa
Postgraduate Scholar, Department of Ophthalmology, SKIMS Medical College, Bemina Srinagar, Jammu and Kashmir, India